(Press-News.org) WASHINGTON—A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.
The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders.
“Early research in both animals and humans suggests that these treatments may help reduce alcohol and other substance use,” said lead researcher Lorenzo Leggio, M.D., Ph.D., of the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), both part of the National Institutes of Health (NIH) in Bethesda, Md. “Some small clinical trials have also shown encouraging results.”
Current Treatment Options Are Limited
Substance use disorders are diagnosed based on criteria that can be grouped into four categories: physical dependence, risky use, social problems, and impaired control.
The negative consequences of substance use disorders represent a global problem, affecting individuals, families, communities, and societal health at large. For instance, research indicates that alcohol is the most harmful drug, with consequences that extend beyond individual health to include related car accidents as well as gun and domestic violence, researchers note.
Despite the high prevalence and consequences of alcohol and other substance use disorders, less than a quarter of people received treatment in 2023.
Underutilization is due to a variety of barriers at the patient, clinician, and organizational levels, not the least of which is the stigma associated with substance use disorders, according to the study. “Current treatments for [alcohol and other substance use disorders] fall short of addressing public health needs,” the researchers wrote.
GLP-1s and Their Potential to Treat Addiction
GLP-1 therapies have gained widespread renown in recent years for their ability to address obesity and significantly reduce weight.
In addition to its inhibitory effects on gastrointestinal systems, GLP-1 has key functions in the central nervous system, the study notes. Among them, GLP-1R activation within the central nervous system curbs appetite and encourages individuals to eat when hungry and stop eating when they are full.
Some forms of obesity have been shown to present biochemical characteristics that resemble addiction, including neurocircuitry mechanisms, the study says, acknowledging that such conclusions are controversial.
“Pathways implicated in addiction also contribute to pathological overeating and obesity,” the study says.
With this pathway in mind, researchers in recent years have looked at GLP-1s as a potential therapy to address substance use disorders. Preclinical and early clinical investigations suggest that GLP-1 therapies modulate neurobiological pathways underlying addictive behaviors, thereby potentially reducing substance craving/use while simultaneously addressing comorbid conditions.
Studies that examine GLP-1 effects on substance use disorders include:
Alcohol use disorder (AUD): A randomized controlled trial with exenatide, the first GLP-1receptor agonist approved for diabetes, showed no significant effect on alcohol consumption, although a secondary analysis indicated reduced alcohol intake in the subgroup of people with AUD and comorbid obesity. A more recent randomized controlled trial showed that low-dose semaglutide — a newer GLP-1 receptor agonist approved for both diabetes and obesity —reduced laboratory alcohol self-administration, as well as drinks per drinking days and craving, in people with AUD.
Opioid use disorder: In rodent models, several GLP-1 receptor agonists have been shown to reduce self-administration of heroin, fentanyl and oxycodone. The studies also found that these medications reduce reinstatement of drug seeking, a rodent model of relapse in drug addiction.
Tobacco use disorder: Preclinical data show that GLP-1 receptor agonists reduce nicotine self-administration, reinstatement of nicotine seeking, and other nicotine-related outcomes in rodents. Initial clinical trials suggest the potential for these medications to reduce cigarettes per day and prevent weight gain that often follows smoking cessation.
Leggio and his colleagues caution that more and larger studies are needed to confirm how well these treatments work. Additional studies will help unveil the mechanisms underlying GLP-1 therapies in relation to addictive behaviors and substance use.
But that hasn’t dampened the optimism for these therapies to address the serious problems found in substance use disorders.
“This research is very important because alcohol and drug addiction are major causes of illness and death, yet there are still only a few effective treatment options,” Leggio said. “Finding new and better treatments is critically important to help people live healthier lives.”
Other study authors are Nirupam M. Srinivasan of the University of Galway in Galway, Ireland; Mehdi Farokhnia of NIDA and NIAAA; Lisa A. Farinelli of NIDA; and Anna Ferrulli of the University of Milan and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica in Milan, Italy.
Research reported in this press release was supported in part by NIDA and NIAAA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
The manuscript, "GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer,” was published online.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on X at @TheEndoSociety and @EndoMedia.
END
GLP-1s show promise in treating alcohol and drug addiction
2025-10-09
ELSE PRESS RELEASES FROM THIS DATE:
Short inspirational videos as effective as meditation at reducing stress
2025-10-09
Watching short inspirational videos may be just as effective at reducing stress as meditation, according to research published by the American Psychological Association.
Stress has arguably reached epidemic levels in the U.S. According to the APA’s Stress in America survey, Americans say they’re feeling more anxious than in previous years, with a majority of people 18-44 saying they feel moderate to extreme stress daily.
“Though there are many effective ways to deal with stress, people often feel too busy or overwhelmed to enact these strategies,” ...
New JNCCN study confirms it’s ‘never too late’ to see survival benefits from quitting smoking—even with late-stage cancer
2025-10-09
PLYMOUTH MEETING, PA [October 9, 2025] — New research published online in JNCCN—Journal of the National Comprehensive Cancer Network finds that people with cancer who quit smoking had a much lower risk of dying within two years compared to those who kept smoking. The researchers followed more than 13,000 individuals with cancer, tracking whether they quit smoking in the first six months after being seen in clinic. The survival benefit was seen across all cancer types and stages, including stages III and IV, where treatment may be less curative. Despite these benefits, only about 1 in 5 smokers quit within six months of their visit.
The Cancer ...
Social and emotional learning programs linked to academic gains
2025-10-09
Washington, October 9, 2025—A new large-scale analysis of existing research finds that school-provided social and emotional learning (SEL) programs improve students’ academic achievement in addition to their social and emotional development. The study appears today in Review of Educational Research, a journal of the American Educational Research Association.
The study was authored by Cheyeon Ha of the University of Southern California, and Michael F. McCarthy, Michael J. Strambler, and Christina Cipriano of the Education Collaboratory at Yale.
In a systematic analysis of 40 studies involving more than 33,700 students in grades 1 through 12, researchers led ...
It’s never too late for those with cancer to quit smoking
2025-10-09
Around 25% of people with cancer in the U.S. are active smokers when they are diagnosed, and studies have found that many of them continue to smoke during treatment. This may be due in part to a common misconception — even among some doctors — that quitting won’t help much if a person already has cancer, particularly if it’s at an advanced stage.
Now, a study led by Li-Shiun Chen, MD, a professor of psychiatry at Washington University School of Medicine in St. Louis, shows that kicking the habit after ...
AIM-HI Accelerator Fund announces winners of the 2025 Venture Competition
2025-10-09
Rockville, MD. (October 9, 2025) – In its mission to accelerate transformative cancer innovations and drive cures forward, the AIM-HI Accelerator Fund is pleased to announce the winners of the 2025 AIM-HI Venture Competition: ResNovas Therapeutics, co-founded by Nobel Laureate Carolyn Bertozzi, Ph.D., Michelle Arkin, Ph.D., CTO Ian Churcher, Ph.D., and CEO Gabriele Sulli, Ph.D.; and Chiara Biosciences, co-founded by National Academy of Inventors Fellow Francis Barany, Ph.D. and CEO Kirsten Flowers, MBA.
The 2025 AIM-HI Venture Competition Committee reviewed more than 80 applications from early-stage oncology ...
American Society of Human Genetics to hold 2025 Annual Meeting next week in Boston
2025-10-09
Rockville, Md. - The American Society of Human Genetics (ASHG) 2025 Annual Meeting will take place October 14-18, 2025 at the Thomas M. Menino Convention & Exhibition Center in Boston, MA. Credentialed members of the press and media are eligible to request complimentary press access to attend the in-person event.
The ASHG 2025 Annual Meeting highlights cutting edge research in genetics and genomics from scientists and clinicians from around the world. Abstracts ...
Newborn genomic screening enables more lifesaving diagnoses
2025-10-09
Adding genomic sequencing to newborn blood screening would detect hundreds of additional childhood conditions, providing much earlier diagnosis and treatment, according to a new study. A baby’s genome, which stays with them for life, could also be re-examined if a health issue arises during their lifetime.
The study, led by Murdoch Children’s Research Institute (MCRI) and Victorian Clinical Genetics Services (VCGS), found genomic screening, a test that reveals a person’s entire genetic ...
AI tool offers deep insight into the immune system
2025-10-09
Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily produce vast amounts of data. For the first time, researchers including those from the University of Tokyo built a software tool which leverages artificial intelligence to not only offer a more consistent analysis of these cells at speed but also categorizes them and aims to spot novel patterns people have not yet seen.
Our immune system is important — it’s impossible to imagine complex life existing without it. This ...
A high-performance supercapacitor made from upcycled water bottles
2025-10-09
Lots of single-use water bottles made from poly(ethylene terephthalate) (PET) end up in landfills, but there’s a growing interest in upcycling them instead. Researchers in ACS’ Energy & Fuels report on new heat-based fabrication methods to transform PET into supercapacitor electrodes and separator films for upcycled energy storage devices. In demonstrations, an all-plastic supercapacitor made from discarded water bottles outperformed a similar design that used a traditional glass fiber separator.
“PET ...
Scientists propose 4 new uses for old veggies
2025-10-09
Food waste is more than just the starting material for compost. From dried-up beet pulp to millipede-digested coconut fibers, scientists are finding treasure in our trash. Four recent papers published in ACS journals detail how food waste contains sustainable solutions for farming and new sources of bioactive compounds for pharmaceuticals. Reporters can request free access to these papers by emailing newsroom@acs.org.
Sugar by-product may “beet” wheat disease. Researchers report in ACS’ Journal of Agricultural and Food Chemistry that sugar beet pulp could help reduce agriculture’s reliance on synthetic pesticides. The pulp, about 80% of the beet’s ...